603301 logo

Zhende Medical
603301

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
CN¥18.73B
EV
CN¥19.34B
Shares Outstanding
265.71M
Beta
0.91
Industry
Medical - Instruments & Supplies

Wall Street View

Analyst Rating
BUY
Analyst Target Price
Number of Analysts
1
P/E 2025E
47.96x
P/Revenue 2025E
3.93x

Historical 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Forecasted 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Margins & Returns

Gross Margin 2025E
33.00%
Net Profit Margin 2025E
8.18%
ROE 2025E
6.70%
ROCE 2024
7.00%

Dividends

DPS 2025E
CN¥0.73
Payout Ratio 2025E
49.66%
Div. Yield 2025E
1.04%
DPS Last 3Y CAGR

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Zhende Medical Co., Ltd.

gainify
603301 logo

Zhende Medical Co., Ltd.

603301

Zhende Medical Co., Ltd. engages in the research and development, production, and sale of medical care and protective equipment in China and internationally. The company offers gauze swab, lap sponge, and fluff gauze swab; non-woven swab; PBT bandage, elastic bandage,...

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Lu, Jianguo

Employees

7,807

IPO Date

2018-04-27

Headquarters

No. 55, Xiangji Road, Gaobu Street, Yuecheng District, Shaoxing, Zhejiang Province, 312035, China

📊 Stock Price & Performance

The last closing price of Zhende Medical (603301) is CN¥70.50, reflecting a -0.35% change from the prior session. Last updated: January 1, 2026 at 2:03 AM Eastern Time

Review the recent 603301 stock performance trends:Past 1 Month: Zhende Medical (603301) shares have -11.07%.Past 3 Months: The stock has +51.09%.Past 6 Months: 603301 shares have +233.96%. Last updated: January 1, 2026 at 12:02 AM Eastern Time

Over the last year, Zhende Medical (603301) has established a 52-week price range between a high of CN¥104.84 and a low of CN¥18.79. This metric is essential for assessing the stock's annual volatility. Last updated: January 1, 2026 at 12:02 AM Eastern Time

Zhende Medical (603301) is considered a medium volatility stock. It has a beta of 0.91, which means it typically moves 0.91 times as much as the broader market. Over the past 52 weeks, 603301 has traded within a CN¥18.79 – CN¥104.84 range. Last updated: January 1, 2026 at 12:02 AM Eastern Time

Based on current 603301 analyst forecasts and market assumptions, the consensus price target for Zhende Medical (603301) is CN¥25.00 for 2027. Relative to the current price of CN¥70.50, this implies a potential downside of -72.35%. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated: January 1, 2026 at 2:03 AM Eastern Time

A CN¥1,000 investment in Zhende Medical 5 years ago, when the stock was trading around CN¥62.52, would be worth approximately CN¥1127.55 today, based solely on share price performance (excluding dividends). This represents a total return of 12.76% over the period, equivalent to a compound annual growth rate (CAGR) of 2.43%. Past performance reflects historical price movements only and does not imply future results. Last updated: January 1, 2026 at 12:02 AM Eastern Time

💰 Financial Metrics & Reports

The current Zhende Medical (603301) market capitalization is approximately CN¥18.73B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Zhende Medical's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:02 AM Eastern Time

In the most recently reported quarter, Zhende Medical (603301) generated CN¥1.08B in revenue, representing a +0.10% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 3:27 AM Eastern Time

In the most recently reported fiscal year, Zhende Medical (603301) generated net income of CN¥385.17M, compared with CN¥198.40M in the prior fiscal year, representing a +94.14% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of CN¥390.00M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 3:27 AM Eastern Time

According to its latest quarterly filing, Zhende Medical (603301) reported EBITDA of CN¥174.23M, representing a -12.32% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 3:27 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.24x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 3:27 AM Eastern Time

Based on the latest available data, Zhende Medical (603301) is currently trading at a last twelve months (LTM) P/E ratio of 66.55x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 3:27 AM Eastern Time

📅 Earnings & Dividends

In the most recently reported quarter, Zhende Medical (603301) revenue was CN¥1.08B. Earnings per share (EPS) for the quarter were CN¥0.28. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 3:27 AM Eastern Time

Zhende Medical (603301) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CN¥0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 3:27 AM Eastern Time

📈 Analyst Information

Analyst assessments of whether Zhende Medical (603301) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: CN¥70.50Consensus price target: CN¥25.00Implied return: -72.35% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 3:27 AM Eastern Time

Based on the latest available analyst coverage, Zhende Medical (603301) currently carries a Buy consensus rating. Analysts' average 603301 price target is CN¥25.00. Relative to the current share price of CN¥70.50, this suggests a potential price change of approximately -72.35%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 3:27 AM Eastern Time

Like other publicly traded stocks, Zhende Medical (603301) shares are bought and sold on stock exchanges such as SHSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Zhende Medical (603301) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 603301 to your watchlist.

Zhende Medical trades under the ticker symbol 603301 on the SHSE stock exchange. The ticker 603301 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Zhende Medical (603301) employs approximately 7,807 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:02 AM Eastern Time

Zhende Medical (603301) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Zhende Medical (603301) stock peers based on overlapping products, services, and competitive dynamics:Allmed Medical Products (002950) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Zhende Medical.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.